Three knee shots go Head-to-Head for lasting arthritis relief

NCT ID NCT05492851

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early This study
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Sep 17, 2026 · Last updated Sep 18, 2026 · Updated 1 time

Summary

Researchers at Ohio State University are running a double-blind, randomized trial to compare three single-dose injections for knee osteoarthritis: Zilretta, Synvisc-One, and Monovisc. The study enrolls adults aged 25 to 85 with painful knee osteoarthritis that continues despite physical therapy and pain medication. Participants receive one of the three injections, and researchers track changes in knee pain and symptoms using a standard questionnaire. The goal is to see whether one injection offers better relief than the others.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
Three injectable knee osteoarthritis treatments: Zilretta, Synvisc-One, and Monovisc
What this could lead to
If one injection works better, doctors could have clearer guidance on which single shot to offer patients whose knee osteoarthritis pain persists after exercise and pain relievers.
What could go wrong
The trial plans to enroll only 6 people, so any differences between the three injections may be too small to trust. Results might not apply to everyone with knee osteoarthritis.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 4

Runs after approval, following long-term safety and how well the treatment works in everyday use.

Participants

6 people

The number who actually took part.

Started

Aug 2022

Finished

Jan 2023

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

25 to 85 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Age 25-85 years * BMI \< 40 * Diagnosis of unilateral knee OA * Radiographic evidence of OA of the target knee (Kellgren-Lawrence grades 2-4) * Continued OA pain in the target knee despite at least 6 weeks of: physical therapy and at least one of the following: activity modification (such as reducing impact on the knee), weight loss, and a 2 week trial of NSAID / acetaminophen. * Knee Osteoarthritis Outcomes Score (KOOS)-Pain subscale 20-65 * Working knowledge of English language (to be able to complete all outcome scores) * Ability to attend all follow-up appointments Exclusion Criteria: * 3+ effusion of the target knee (stroke test grading system) * Prior injection therapy: * Steroid injection in target knee in the last 3 months * Viscosupplementation in target knee in the last 6 months * PRP in the target knee in the last 6 months * Cellular treatments in index knee (bone marrow, amniotic suspensions etc) 1 year * Participation in any experimental device or drug study within 1 year before screening visit * Oral or IM steroids in the last 3 months (Inhaled steroids used in the treatment of asthma/allergies are permitted) * Medical condition that may impact outcomes of procedure including: * Systemic inflammatory disorders that impact the joints like rheumatoid arthritis, lupus, etc * Undergoing current cancer treatment (other than non-melanoma skin malignancies) * Taking immunosuppressants * Previous cartilage repair procedure on the injured cartilage surface (ie, OATS, ACI, MFX) in the last 5 years * Previous surgery at the target knee within the past 1 year * Any degree of cognitive impairment * Symptomatic OA of any other joint in the lower limbs * Pregnancy, lactating, or intent to become pregnant during treatment period (Female participants will be asked if they are pregnant, lactating, or intend to become pregnant during treatment) * Gout, Pseudogout (including radiographic evidence of chondrocalcinosis) * History of infection or current infection at the affected joint * Smoking (Former smokers\< 1 year from quit date)

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Osteoarthritis, knee are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • Jameson Crane Sports Medicine Institute

    Columbus, Ohio, 43202, United States

  • Ohio State Outpatient Lewis Center

    Lewis Center, Ohio, 43035, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.